Blood Product Supply

Data about the links between Coronavirus disease 2019(COVID-19) and the safety of blood products during the pandemic is inadequate. During the COVID-19 pandemic, high volumes of patients receiving blood products due to post-terminal surgical complications depleted stores for the entire hospital, resulting in surgeons unable to acquire emergent blood products. Data from this study can be used to develop a policy on how to handle blood shortage issues during this and future pandemics. Also, this data can be used to determine future policies on use of blood products from COVID-19-positive donors.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

COVID-19 Coronaviridae Infections Coronavirus Infections Infections Lung Diseases Nidovirales Infections Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Methodist Dallas Medical Center- Clinical Research Institute

Dallas, Texas, 75203, United States

About this study

To identify the circumstances associated with observed delays in receiving blood products to use in emergent cases.
Determine the cost/benefit of moribund patients receiving massive transfusion during the COVID-19 pandemic.
Quantify COVID-19 diagnosis and complications in patients arriving with no indication of disease at index admission as relative to in hospital or blood product exposure.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

>_18 years of age Surgical patients treated at Methodist Dallas Medical Center(MDMC)

Exclusion criteria

<18 years of age Prisoners Pregnant women

Treatment and study plan

Document delays and frequencies of inadequate blood products for emergent cases

Other

The COVID-19 pandemic is contributing to delays in blood product acquisition and inadequate blood product supplies for emergent cases in hospitals

Primary outcomes

Time frame

Time frame: 1 year

Dates of inadequate or delayed blood products for emergent cases during the timeframe of the COVID-19 pandemic (March 2020 to March 2021) to be compared relative to number of days or cases where no shortages were noted

Sponsors and collaborators

Lead sponsor

Methodist Health System

Other

Registry information

Official study title

Blood Product Supply During COVID-19

Important dates

Study start: 2020
Primary completion: 2021
Study completion: 2025
First posted: Mar 24, 2026
Registry last updated: Mar 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed